Form 4: Spero Therapeutics Director Patrick Vink Granted 20,000 Restricted Stock Units

Spero Therapeutics, Inc. Director Patrick V.J.J. Vink was granted 20,000 restricted stock units (RSUs) on June 12, 2025, increasing his total beneficial ownership to 75,000 shares.

Summary

• Patrick V.J.J. Vink, a Director of Spero Therapeutics, Inc. (SPRO), acquired 20,000 shares of common stock on June 12, 2025.
• These shares were granted as Restricted Stock Units (RSUs), with each RSU representing the right to receive one share of common stock upon vesting.
• The RSUs were granted at a price of $0 per unit, indicating they are part of a compensation package.
• The newly granted RSUs are scheduled to vest on June 12, 2026, contingent upon Mr. Vink's continued service to the company.
• Following this transaction, Mr. Vink's total beneficial ownership in Spero Therapeutics, Inc. stands at 75,000 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued director engagement and alignment of interests with shareholders, which is generally viewed favorably.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The continued grant of equity compensation to a director suggests ongoing commitment and retention of key board members.

Future Outlook

The vesting schedule of the RSUs on June 12, 2026, implies an expectation of continued service from Director Patrick V.J.J. Vink for at least another year.

Industry Context

The grant of Restricted Stock Units (RSUs) is a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, including companies like Spero Therapeutics. This practice is widely used to incentivize long-term performance and align the interests of leadership with those of shareholders.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing its leadership.

Next Steps

• The 20,000 Restricted Stock Units are expected to vest on June 12, 2026, assuming the reporting person's continued service.

Key Dates

Keywords

Spero Therapeutics, SPRO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Beneficial Ownership, Equity Grant